PMPRB closes all open drug-pricing investigations before implementing new guidelines on Jan. 1
But that doesn’t mean the drug pricing tribunal can’t look at past years’ data to inform future reviews of drug prices, says director general Guillaume Couillard.
The Patented Medicine Prices Review Board has closed any outstanding investigations into excessive pricing in order to start “fresh” when updated guidelines are implemented in the new year, says its director general.
Get Today's Headlines Newsletter
Wake up to the day's top political and policy headlines. Weekday Mornings.
By entering your email address you consent to receive email from The Hill Times containing news, analysis, updates and offers. You may unsubscribe at any time. See our privacy policy
